Acute and chronic acetaminophen use and renal disease: A case-control study using pharmacy and medical claims

Journal of Managed Care Pharmacy

Volumn 18, Issue 3, 2012, Pages 234-246

  Kelkar, Mugdha ^a   Cleves, Mario A ^b   Foster, Howell R ^c   Hogan, William R ^b   James, Laura P ^b   Martin, Bradley C ^c  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CARBAMAZEPINE; CISPLATIN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; ICD-9-CM; KIDNEY DISEASE; MALE; MEDICAID; MEDICAL RECORD REVIEW; MEDICARE; NEPHRITIS; PHARMACEUTICAL CARE; PHARMACY; PRESCRIPTION; PREVALENCE; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84860765311     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.3.234     Document Type: Article

References (51)

1. Patterns of medication use in the United States. A report from the Slone Survey. 2004. Available at: http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyReport2004.pdf. Accessed March 11, 2012.
2. U.S. Food and Drug Administration. The Acetaminophen Hepatotoxicity Working Group. Recommendations for FDA interventions to decrease the occurrence of acetaminophen hepatotoxicity. February 26, 2008. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM 164898.pdf. Accessed March 11, 2012.
3. Herper M. America's most popular drugs. Forbes. May 11, 2010. Available at: http://www.forbes.com/2010/05/11/narcotic-painkiller-vicodin-businesshealthcare-popular-drugs.html. Accessed March 11, 2012.
4. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15(6):398-405.
5. Li C, Martin BC. Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993-2007. Pharmacoepidemiol Drug Saf. 2011;20(8):810-18.
6. Blantz RC. Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis. 1996;28(1 Suppl 1):S3-S6.
7. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol. 2001;31(1):55-138.
8. Ghosh J, Das J, Manna P, Sil PC. Acetaminophen induced renal injury via oxidative stress and TNF-alpha production: therapeutic potential of arjunolic acid. Toxicology. 2010;268(1-2):8-18.
9. Waring WS, Jamie H, Leggett GE. Delayed onset of acute renal failure after significant paracetamol overdose: a case series. Hum Exp Toxicol. 2010;29(1):63-68.
10. Hengy B, Hayi-Slayman D, Page M, et al. Acute renal failure after acetaminophen poisoning: report of three cases. Can J Anaesth. 2009;56(10):770-74.
11. Jeffery WH, Lafferty WE. Acute renal failure after acetaminophen overdose: report of two cases. Am J Hosp Pharm. 1981;38(9):1355-58.
12. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy- an autopsy study. Nephrol Dial Transplant. 2006;21(11):3139-45.
13. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345(25):1801-08.
14. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med. 1983;143(9):1687-93.
15. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol. 1989;9(5):403-12.
16. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med. 1989;320(19):1238-43.
17. van der Woude FJ, Heinemann LA, Graf H, et al. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol. 2007;8:15. Available at: http://www.biomedcentral.com/content/pdf/1471-2369-8-15.pdf. Accessed March 11, 2012.
18. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-37.
19. Gokhale M, Martin BC. Prescription-acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiol Drug Saf. 2012;21(2):226-30.
20. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan BJ, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138(2):440-49.
21. Albertson TE, Walker VM, Jr., Stebbins MR, Ashton EW, Owen KP, Sutter ME. A population study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann Pharmacother. 2010;44(7-8):1191-95.
22. Waikar SS, Wald R, Chertow GM, et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification codes for acute renal failure. J Am Soc Nephrol. 2006;17(6):1688-94. Available at: http://jasn.asnjournals.org/content/17/6/1688.full.pdf+html. Accessed March 11, 2012.
23. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483-87.
24. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-75. Available at: http://jama.ama-assn.org/content/285/18/2370.full.pdf+html. Accessed March 11, 2012.
25. Ljungman S. The kidney as a target of hypertension. Curr Hypertens Rep. 1999;1(2):164-69.
26. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA. 1996;275(3):189-93.
27. Stavem K, Lossius MI, Kvien TK, Guldvog B. The health-related quality of life of patients with epilepsy compared with angina pectoris, rheumatoid arthritis, asthma and chronic obstructive pulmonary disease. Qual Life Res. 2000;9(7):865-71.
28. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol. 1995;6(1):48-53.
29. Pollock DA, Boyle CA, DeStefano F, Moyer LA, Kirk ML. Underreporting of alcohol-related mortality on death certificates of young US Army veterans. JAMA. 1987;258(3):345-48.
30. Stropp C. Diabetes leading cause of kidney failure. Aust Nurs J. 2008;16(1):35.
31. Puffer RR. New approaches for epidemiologic studies of mortality statistics. Bull Pan Am Health Organ. 1989;23(4):365-83.
32. Edlund MJ, Martin BC, Fan MY, Devries A, Braden JB, Sullivan MD. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010;112 (1-2):90-98.
33. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2(2):80-91. Available at: http://www.nature. com/nrneph/journal/v2/n2/pdf/ncpneph0076.pdf. Accessed March 11, 2012.
34. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-89. Available at: http://aje.oxfordjournals. org/content/164/9/881.long. Accessed March 11, 2012.
35. Hosmer DH, Lemeshow S. Interpretation of the fitted logistic regression model. In: Hosmer DH, Lemeshow S, eds. Applied Logistic Regression. 2nd ed. Hoboken NJ: John Wiley and Sons; 2000.
36. Chongsuvivatwong V. Analysis of epidemiological data using R and Epicalc. January 1, 2010. Epidemiology Unit, Prince of Songkla University, Thailand. Available at: http://www.cran.r-project.org/doc/contrib/Epicalc_ Book.pdf. Accessed March 11, 2012.
37. Zhao L, Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev. 2011;43(1):41-52.
38. Djulbegovic B, Hozo I, Lyman GH. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. MedGenMed. 2000;2(1):E6. Available at: http://slaopweb.org/pdf/MBOncology/Journ8.pdf. Accessed March 11, 2012.
39. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42(4):677-84.
40. Peacock PR. Management of acute complications of acute renal failure. Medscape. May 2, 2011 Available at: http://emedicine.medscape.com/article/777845-overview. Accessed March 11, 2012.
41. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-07.
42. Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med. 1996;100(2A):31S-36S.
43. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy- report of the ISPOR risk-benefit management working group. Value Health. 2010;13(5):657-66. Available at: http://www.ispor.org/workpaper/risk_benefit_ management_guo.pdf. Accessed March 11, 2012.
44. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting- what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila). 2009;47(8):784-89.
45. Johnson & Johnson. McNeil Consumer Healthcare announces plans for new dosing instructions for Tylenol products. July 28, 2011. Available at: http://www.jnj.com/connect/news/all/mcneil-consumer-healthcare-announces-plans-for-new-dosing-instructions-for-tylenol-products. Accessed March 11, 2012.
46. U.S. Food and Drug Adminisration. Acetaminophen information. March 7, 2012. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm165107.htm. Accessed March 11, 2012.
47. Temple AR, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the longterm (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28(2):222-35.
48. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36(9):1196-206.
49. Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminopheninduced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999;29(2):451-63.
50. Dalhoff K, Laursen H, Bangert K, et al. Autoprotection in acetaminophen intoxication in rats: the role of liver regeneration. Pharmacol Toxicol. 2001;88(3):135-41.
51. Kuffner, E. Improving patient's awareness of acetaminophen in over the-counter (OTC) and prescription (Rx) medicines: "APAP" OFF and Icon ON. FDA public workshop. June 24, 2010. Available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM218768.pdf. Accessed March 11, 2012.